Rapid preparation of mutated influenza hemagglutinins for influenza virus pandemic prevention
© Nishioka et al. 2016
Received: 12 December 2015
Accepted: 12 January 2016
Published: 21 January 2016
Influenza viruses have periodically caused pandemic due to frequent mutation of viral proteins. Influenza viruses have two major membrane glycoproteins: hemagglutinin (HA) and neuraminidase (NA). Hemagglutinin plays a crucial role in viral entry, while NA is involved in the process of a viral escape. In terms of developing antiviral drugs, HA is a more important target than NA in the prevention of pandemic, since HA is likely to change the host specificity of a virus by acquiring mutations, thereby to increase the risk of pandemic. To characterize mutated HA functions, current approaches require immobilization of purified HA on plastic wells and carriers. These troublesome methods make it difficult to respond to emerging mutations. In order to address this problem, a yeast cell surface engineering approach was investigated. Using this technology, human HAs derived from various H1N1 subtypes were successfully and rapidly displayed on the yeast cell surface. The yeast-displayed HAs exhibited similar abilities to native influenza virus HAs. Using this system, human HAs with 190E and 225G mutations were shown to exhibit altered recognition specificities from human to avian erythrocytes. This system furthermore allowed direct measurement of HA binding abilities without protein purification and immobilization. Coupled with the ease of genetic manipulation, this system allows the simple and comprehensive construction of mutant protein libraries on yeast cell surface, thereby contributing to influenza virus pandemic prevention.
KeywordsInfluenza Hemagglutinin Yeast display Hemagglutination assay
Influenza viruses have caused pandemic in humans as well as in animals (Potter 2001; Capua and Alexander 2008). The human influenza viruses recognize human-specific cell receptors via α2,6-linked sialic acid side chains on surface glycoproteins, while avian influenza viruses recognize avian-specific cell receptors via α2,3-linked sialic acid side chains on surface glycoproteins (Gagneux et al. 2003; Ito and Kawaoka 2000). These subtle differences in sialic acid recognition are key in preventing animal influenza viruses from infecting humans; however, some influenza viruses infecting animals have acquired the potency to overcome this difference (Van Reeth 2007). Highly pathogenic avian influenza viruses including H5N1 subtypes have been reported to alter their targets from avian to human, causing 447 deaths until 2010 (Webby and Webster 2003; WHO 2015). Recently, the swine influenza virus also acquired the ability to infect humans via genetic re-assortment (Zhou et al. 1999). The swine influenza virus was transmitted widely among humans, resulting in the first influenza pandemic in the twenty first century (Kuiken et al. 2011). Swine may play roles as intermediate hosts for influenza viruses between humans and avian species because swine cell receptors have both the α2,6- and the α2,3-linked sialic acid side chains on their surface glycoproteins (Ito and Kawaoka 2000). When human influenza viruses and avian influenza viruses infect the same intermediate host, gene re-arrangement between the human and avian influenza viruses is likely to occur, enabling the viruses to alter their recognition preferences of sialic acid on surface glycoprotein (Dawood et al. 2009). Indeed, the influenza virus pandemic is thought to have emerged from gene re-assortment of the North American H3N2 human-like viruses and the H1N2 swine viruses with Eurasian avian-like swine viruses (Dawood et al. 2009). The re-assortment process enables animal influenza viruses to effectively develop the capacity to infect humans (Zhou et al. 1999), which suggests that the threat of infection caused by new influenza viruses will continue as the differences between human and animal viruses are overcome.
Influenza viruses have two major surface membrane glycoproteins: neuraminidase (NA) and hemagglutinin (HA) (Air and Laver 1989; Skehel and Wiley 2000). While NA is involved in the process by which newly generated viruses escape from host cells (Air and Laver 1989), HA, which forms a trimer embedded on the viral envelope surface, is responsible for binding and entry into host cells (Skehel and Wiley 2000). Each monomer of HA is synthesized as a single polypeptide (HA0) that is cleaved by host proteases into two subunits (HA1 and HA2) (Skehel and Wiley 2000), of which HA1 represents an active head region that binds to sialic acid side chains on surface glycoproteins and HA2 represents a stem region that is required for membrane fusion activity and infectivity (Skehel and Wiley 2000). Both NA and HA are frequently mutated in the life cycle of the influenza virus, resulting in high levels of antigenic variation (Domingo and Holland 1997).
The high mutation rate of HA sometimes generates new HA subtypes that have never infected humans. Some mutations have already been reported to contribute to the changes in the binding abilities of HA from avian to human receptors or from human to avian receptors, which were, in part, responsible for the pandemic (Stevens et al. 2006). Inhibition of HA prevents the infection as a first attack caused by influenza virus mutants. Various methods including phage display have been used to screen for inhibitors that bind to the target domains (Hawkins et al. 1992; Matsubara et al. 2010; Krag et al. 2006); however, these current approaches would not be sufficient to deal with influenza viruses for the following reasons. Firstly, in order to discriminate the binding abilities of HA mutants, purified HA needs to be immobilized on plastic wells or carriers (Hawkins et al. 1992; Matsubara et al. 2010). Secondly, frequent mutations make it difficult to deal with HA mutants because time-consuming methods are required for each mutant preparation. In order to address these problems, a novel method for dealing with the high mutation rate of the influenza virus must be developed.
We previously reported on the successful display of various head domains of the wild-type and drug-resistant NAs from the avian H5N1 virus on yeast cell surface using yeast cell surface engineering in Saccharomyces cerevisiae (Shigemori et al. 2013). In this system, a protein of interest can be displayed on yeast cell surface as a fusion protein with α-agglutinin, which is a cell wall protein involved in mating (Murai et al. 1997; Ueda and Tanaka 2000). This method allows direct measurement of the protein activity without protein purification steps (Ueda and Tanaka 2000).
Here, we report on the construction of two kinds of yeasts displaying either human short HA (hSHAα2,6) or human long HA (hLHAα2,6) from the human H1N1 virus. hSHAα2,6 consists of the domain that binds to α2,6-linked sialic acid side chains, while hLHAα2,6 consists of the binding domain and the stem region without the secretion signal peptide and the transmembrane domain. hSHAα2,6 and hLHAα2,6 displayed on the yeast cell surface were shown to recognize α2,6-linked sialic acid side chains on the surface glycoproteins of erythrocytes. The cell surface display of human HA mutants with altered binding specificity by induction of mutations was furthermore shown to result in direct detection of recognizing α2,3-linked sialic acid side chains on chicken erythrocytes. The system reported on here was shown to rapidly prepare HA mutants on cell surface and to allow for easy analysis of the functions of these mutants coupled with easy genetic manipulation of yeast. Our yeast cell surface system therefore allows for the simple and comprehensive construction of HA and NA mutant libraries on yeast cell surface, thereby facilitating the prevention of pandemic caused by influenza viruses.
Materials and methods
Microbial strains and culture media
The DH5α (F−, endA1, hsdR17[r k − /m K + ], supE44, thi-1, λ −, deoR, recA1, gyrA96, phoA, φ80dlacZΔM15, Δ[lacZYA-argF]U169) Escherichia coli strain (Toyobo, Osaka, Japan) was used as the host for recombinant DNA manipulation. S. cerevisiae BY4741/sed1Δ (MAT a, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0, YDR077w::KanMX4) (EUROSCARF, Frankfurt, Germany) was used for displaying HA. E. coli transformants were grown at 37 °C in Luria–Bertani medium (1 % [w/v] tryptone, 0.5 % [w/v] yeast extract, and 1 % [w/v] sodium chloride) containing 50 μg/mL ampicillin. Yeast transformants were selected on a synthetic dextrose (SDC) solid medium (0.67 % [w/v] yeast nitrogen base without amino acids, 2 % [w/v] glucose, 1 % [w/v] casamino acids, 0.002 % [w/v] adenine, 0.002 % [w/v] l-tryptophan, 2 % [w/v] agar). Isolated transformant colonies were aerobically cultivated at 30 °C in a liquid SDC medium buffered with 5 mM 2-morpholinoethanesulfonic acid (MES; pH 6.5).
Vectors for cell surface display of human HA
The primers used in this study are listed in Additional file 1: Table S1. The human HA gene was derived from the Influenza A H1N1 (A/New Caledonia/20/99) HA ORF mammalian expression plasmid (Sino Biological, Beijing, China). The DNA fragments encoding a binding domain (human short HA, amino acid residues No. 36–268) or encoding a binding domain and stem region (human long HA, amino acid residues No. 14–515) were PCR-amplified from the plasmid using the appropriate primers (“human short HA Forward” and “human short HA Reverse” for human short HA, or “human long HA Forward” and “human long HA Reverse” for human long HA). The DNA fragments were inserted into BglII/XhoI-digested pULD1 (Kuroda et al. 2009), which encodes the C-terminal half of α-agglutinin downstream of the multiple cloning sites, using an In-Fusion HD Cloning kit (Clontech, Mountain view, CA). The resultant plasmids were named pULD-hSHAα2,6 and pULD-hLHAα2,6. The plasmids used for displaying the head domain recognizing α2,3-linked sialic acid side chains on surface glycoproteins were constructed by mutating pULD-hSHAα2,6 or pULD-hLHAα2,6 using a QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA) and the “N190E Forward” and “N190E Reverse” or “D225G Forward” and “D225G Reverse” primers. The resultant plasmids were named pULD-hSHAα2,6* and pULD-hLHAα2,6*, respectively. pULD1-strep displaying a strep-tag instead of a FLAG-tag, was used as a negative control for immunofluorescence staining (Kuroda et al. 2009).
Transformation of yeast
Yeasts were transformed using the Frozen-EZ Yeast Transformation-II kit (Zymo Research, Irvine, CA). After the introduction of plasmids, the yeast transformants were selected on a uracil-deficient SDC solid medium.
Collection and preparation of red blood cells
Rabbit, chicken, horse (Nippon Biotest Laboratories, Tokyo, Japan), and swine (Funakoshi, Tokyo, Japan) erythrocytes were used for the HA assay. Aliquots (4 mL) of erythrocytes were washed three times with phosphate-buffered saline (PBS; pH 7.4) by centrifugation at 100×g for 10 min, and were then resuspended in PBS (pH 7.4) at final working solution (1.0 %).
Yeast transformants were precultivated in buffered SDC medium (pH 6.5) for 24 h and the main cultivation was initiated at an initial optical density (OD600) of 0.1 in 10 mL buffered SDC medium (pH 6.5). After 72 h cultivation at 30 °C, the cells were harvested and resuspended to 2.0 × 108 cells/mL. Cell suspensions (50 µL) were diluted 2-, 4-, and 8-fold with PBS (pH 7.4) in a 96-well microplate (FALCON 353910, CA). The yeast cells were mixed with 50 μL erythrocyte suspension (1.0 %) and incubated at 25 °C for 2 h. Active HA yields the “cross-linked structure”, while HA lacking binding ability forms “dot-like aggregation” in the center of the well (see Fig. 2). To investigate the relative binding abilities of HA, a quantitative analysis of dot-like aggregation in the well was performed using ImageJ software (National Institutes of Health, MD) (Lazic 2009). Images were analyzed after background correction using the rolling ball radius tool (50 pixels). The area of “dot-like aggregation” of erythrocytes within each negative control well (OD600 = 10) was defined as the measurement area, which was then used to evaluate erythrocyte levels as raw integrated density values (sum of pixel values) in other wells (OD600 = 10) (Lazic 2009). The results of this analysis were shown as the ratio to negative controls from each of six separate images (Additional file 1: Figure S1). Differences found to be significant by the Steel–Dwass test (P < 0.01) were considered to be indicative of HA binding ability.
A total of 3.0 × 107 yeast cells were washed once with 1 mL PBS (pH 7.4) and then resuspended in PBS (pH 7.4) containing 1.0 % (w/v) bovine serum albumin. The yeast cells were incubated at room temperature for 30 min with rotary shaking (25 rpm; RT-50, TAITEC, Saitama, Japan). The yeast cells were incubated with an anti-FLAG M2 mouse monoclonal antibody (Sigma–Aldrich, MO) at a 1:300 dilution for 1.5 h at room temperature. The yeast cells were washed with PBS (pH 7.4) and mixed with Alexa Flour 488-conjugated anti-mouse IgG antibody (Invitrogen, Carlsbad, CA) at a 1:300 dilution for 1 h at room temperature. After washing twice with PBS (pH 7.4), the yeast cells were resuspended to 108 cells/mL by PBS (pH 7.4) for fluorescence observation. Fluorescence was detected using an inverted microscope (Olympus IX71, Tokyo, Japan) through a U-MNIBA2 mirror unit with a BP470–490 excitation filter, DM505 dichroic mirror, and a BA510–550 emission filter (Olympus). Live images were obtained using Aqua-Cosmos 2.0 software (Hamamatsu Photonics, Shizuoka, Japan) controlling a digital charge-coupled device camera (C4742-95-12ER, Hamamatsu Photonics). To determine the display efficiency, the fluorescence intensities were measured by using a Fluoroskan Ascent Fluorometer (Labsystems, Helsinki, Finland) with excitation and emission wavelengths of 485 and 527 nm, respectively. A total of 2.0 × 107 yeast cells were used for measurement.
Display of human HAs on the yeast cell surface
Binding abilities of yeast-displayed human HAs
Binding preferences of mutated human HAs on yeast cell surfaces
To further characterize HA on the yeast cell surface, we investigated whether the altered binding site affected the recognition properties of the displayed HA. On the virus surface, HA distinguishes between α2,3- and α2,6-linked sialic acid side chains (Ito et al. 1997). In general, influenza viruses isolated from humans bind to α2,6- but not α2,3-linked sialic acid side chains (Gagneux et al. 2003); however, the 190E and 225G mutations in HAs derived from the human H1 subtype reportedly yielded a change in recognition from α2,6- to α2,3-linked sialic acid side chains (Tumpey et al. 2007). Recognition change can be confirmed using erythrocytes from different hosts (Ito et al. 1997). Chicken erythrocytes, for example, contain more α2,3- than α2,6-linked sialic acid side chains, while rabbit erythrocytes contain mainly α2,6-linked sialic acid side chains (Tumpey et al. 2007). We investigated in this study whether the introduction of two point mutations (N190E and D225G) into hHAsα2,6 altered the recognition from α2,6- to α2,3-sialic acid side chains. Human-based short HA (hSHAα2,6*) and human-based long HA (hLHAα2,6*) were constructed by introducing the two point mutations (N190E and D225G) into hSHAα2,6 and hLHAα2,6 (Additional file 1: Figure S2). Display of hSHAα2,6* and hLHAα2,6* on yeast cells was confirmed by immunofluorescence (Fig. 1b, c). The yeast-displayed hSHAα2,6* and hLHAα2,6* exhibited binding capabilities for α2,3-linked sialic acid side chains on surface glycoproteins of erythrocyte derived from chicken, while hHAsα2,6 did not (Fig. 3b; Additional file 1: Figure S1). Therefore, the two point mutations were shown to alter recognition from α2,6- to α2,3-linked sialic acid side chains, suggesting that the HAs on yeast cell surfaces exhibited similar binding characteristics to those of native HAs on the virus.
The binding preferences of hHAsα2,6 and hHAsα2,6* (hSHAα2,6* and hLHAα2,6*) toward horse and swine erythrocytes were investigated. Horse erythrocytes contain mainly α2,3-linked sialic acid side chains on surface glycoproteins and swine erythrocytes contain both α2,3- and α2,6-linked sialic acid side chains on their surface glycoproteins (Ito et al. 1997). hHAsα2,6* was shown to form cross-linkages with the horse erythrocytes (Fig. 3c; Additional file 1: Figure S1) and in the case of the swine erythrocytes, both hHAsα2,6 and hHAsα2,6* formed cross-linkages (Fig. 3d; Additional file 1: Figure S1). Overall, hHAsα2,6 were therefore shown to recognize rabbit and swine erythrocytes, while hHAsα2,6* was shown to recognize chicken, horse, and swine erythrocytes. These recognition specificities are consistent with the distribution of sialic acid side chains on the respective surface glycoproteins (Ito et al. 1997; Medeiros et al. 2001).
Hemagglutination assay with erythrocytes from different animal species
Hemagglutination with erythrocytes from
α2, 6 << α2, 3
α2, 6 = α2, 3
Binding activity of HAsα2,6
Binding activity of HAsα2,6*
In the yeast cell surface engineering reported here, both hSHAα2,6 and hLHAα2,6 were successfully displayed on the yeast cell surface (Fig. 1b). Both hSHAα2,6 and hLHAα2,6 were shown to have similar binding capabilities (Fig. 3a; Additional file 1: Figure S1), suggesting that the yeast-displayed hLHAα2,6 did not require protease-mediated cleavage for its binding capabilities (Stevens et al. 2006). Glycan arrays have been used to investigate the binding abilities of HA (Stevens et al. 2006; Kumari et al. 2007). For such glycan arrays, HA cleavage by protease treatments was not required for assessments of the binding abilities of HA (Stevens et al. 2006; Kumari et al. 2007). Similarly, HAs displayed on yeast cell surfaces exhibited binding abilities without HA processing by exogenous proteases. Unlike glycan arrays (Stevens et al. 2006; Kumari et al. 2007), yeast cell surface engineering does not require time-consuming purification and immobilization steps. In glycan arrays, HA must be directly or indirectly labelled with a fluorescent tag to allow for binding events to be detected (Stevens et al. 2006). Because of the weak affinity of HA for sialic acids of proteins, glycan arrays sometimes fail to detect binding events (Stevens et al. 2006; Sauter et al. 1989). The display of HA on yeast cell surfaces, on the other hand, may represent a convenient approach by which HA binding specificities can be confirmed.
Recombinant baculoviruses are widely used to express HA genes in cultured insect cells (Wang et al. 2006; Treanor et al. 2013); however, HA production using this approach may take more than a month (Wang et al. 2006; Treanor et al. 2013). With the yeast display method, on the other hand, HA can be prepared within several days and does not require purification.
Human HA consisting of only the binding site (hSHA) was displayed approximately 1.5 times more effectively than human HA consisting of both the binding site and the stem region (hLHA) (Fig. 1b, c). The molecular mass of displayed proteins on the yeast cell surface affects fluorescence intensities of cells after immunofluorescent staining (Nishitani et al. 2010; Shibasaki et al. 2001). Both hSHA and hLHA exhibited binding abilities; however, hLHA-displaying yeasts would be more useful in inhibitor screening assays since it is more likely that inhibitors would bind not only to the binding site but also to the stem region.
In conclusions, a yeast cell surface system reported on here allows for direct measurement of the binding abilities of HAs without protein purification steps and thus would allow for the preparation of an HA mutant library as well as an NA mutant library as previously reported (Shigemori et al. 2013). This application would be advantageous in the analysis of newly emerging influenza virus mutants, thereby contributing to the prompt development of antiviral drugs. This yeast cell surface display system would therefore contribute to the prevention of influenza virus pandemics caused by frequent viral mutations.
This work was partly supported by JST, CREST.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Air GM, Laver WG. The neuraminidase of influenza virus. Proteins. 1989;6(4):341–56.View ArticlePubMedGoogle Scholar
- Capua I, Alexander DJ. Ecology, epidemiology and human health implications of avian influenza viruses: why do we need to share genetic data? Zoonoses Public Health. 2008;55(1):2–15.View ArticlePubMedGoogle Scholar
- Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605–15.View ArticlePubMedGoogle Scholar
- Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151–78.View ArticlePubMedGoogle Scholar
- Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden EC, Anderson D, McClure H, Varki A, Varki NM. Human-specific regulation of α2-6-linked sialic acids. J Biol Chem. 2003;278(48):48245–50.View ArticlePubMedGoogle Scholar
- Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992;226(3):889–96.View ArticlePubMedGoogle Scholar
- Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida H, Paulson JC, Webster RG, Kawaoka Y. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol. 1998;72(9):7367–73.PubMed CentralPubMedGoogle Scholar
- Ito T, Kawaoka Y. Host-range barrier of influenza A viruses. Vet Microbiol. 2000;74(1–2):71–5.View ArticlePubMedGoogle Scholar
- Ito T, Suzuki Y, Mitnaul L, Vines A, Kida H, Kawaoka Y. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology. 1997;227(2):493–9.View ArticlePubMedGoogle Scholar
- Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006;66(15):7724–33.View ArticlePubMedGoogle Scholar
- Kuiken T, Fouchier R, Rimmelzwaan G, van den Brand J, van Riel D, Osterhaus A. Pigs, poultry, and pandemic influenza: how zoonotic pathogens threaten human health. Adv Exp Med Biol. 2011;719:59–66.View ArticlePubMedGoogle Scholar
- Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007;4:42.PubMed CentralView ArticlePubMedGoogle Scholar
- Kuroda K, Matsui K, Higuchi S, Kotaka A, Sahara H, Hata Y, Ueda M. Enhancement of display efficiency in yeast display system by vector engineering and gene disruption. Appl Microbiol Biotechnol. 2009;82(4):713–9.View ArticlePubMedGoogle Scholar
- Lazic SE. Statistical evaluation of methods for quantifying gene expression by autoradiography in histological sections. BMC Neurosci. 2009;10:5.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsubara T, Onishi A, Saito T, Shimada A, Inoue H, Taki T, Nagata K, Okahata Y, Sato T. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem. 2010;53(11):4441–9.View ArticlePubMedGoogle Scholar
- Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. Hemagglutinin residues of recent human A (H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology. 2001;289(1):74–85.View ArticlePubMedGoogle Scholar
- Murai T, Ueda M, Yamamura M, Atomi H, Shibasaki Y, Kamasawa N, Osumi M, Amachi T, Tanaka A. Construction of a starch-utilizing yeast by cell surface engineering. Appl Environ Microbiol. 1997;63(4):1362–6.PubMed CentralPubMedGoogle Scholar
- Nishitani T, Shimada M, Kuroda K, Ueda M. Molecular design of yeast cell surface for adsorption and recovery of molybdenum, one of rare metals. Appl Microbiol Biotechnol. 2010;86(2):641–8.View ArticlePubMedGoogle Scholar
- Potter CW. A history of influenza. J Appl Microbiol. 2001;91(4):572–9.View ArticlePubMedGoogle Scholar
- Sauter NK, Bednarski MD, Wurzburg BA, Hanson JE, Whitesides GM, Skehel JJ, Wiley DC. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry. 1989;28(21):8388–96.View ArticlePubMedGoogle Scholar
- Shibasaki S, Ueda M, Iizuka T, Hirayama M, Ikeda Y, Kamasawa N, Osumi M, Tanaka A. Quantitative evaluation of the enhanced green fluorescent protein displayed on the cell surface of Saccharomyces cerevisiae by fluorometric and confocal laser scanning microscopic analyses. Appl Microbiol Biotechnol. 2001;55(4):471–5.View ArticlePubMedGoogle Scholar
- Shigemori T, Nagayama M, Yamada J, Miura N, Yongkiettrakul S, Kuroda K, Katsuragi T, Ueda M. Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases. FEBS Open Bio. 2013;3:484–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–69.View ArticlePubMedGoogle Scholar
- Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol. 2006a;355(5):1143–55.View ArticlePubMedGoogle Scholar
- Stevens J, Blixt O, Paulson JC, Wilson IA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol. 2006b;4(11):857–64.View ArticlePubMedGoogle Scholar
- Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006c;312(5772):404–10.View ArticlePubMedGoogle Scholar
- Stieneke-Grober A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk HD, Garten W. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 1992;11(7):2407–14.PubMed CentralPubMedGoogle Scholar
- Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Goldenthal KL, Kohberger R, Dunkle LM. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant. Vaccine. 2013;31(48):5760–5.View ArticlePubMedGoogle Scholar
- Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM, Garcia-Sastre A. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science. 2007;315(5812):655–9.View ArticlePubMedGoogle Scholar
- Ueda M, Tanaka A. Genetic immobilization of proteins on the yeast cell surface. Biotechnol Adv. 2000;18(2):121–40.View ArticlePubMedGoogle Scholar
- Van Reeth K. Avian and swine influenza viruses: our current understanding of the zoonotic risk. Vet Res. 2007;38(2):243–60.View ArticlePubMedGoogle Scholar
- Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin–one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24(12):2176–85.View ArticlePubMedGoogle Scholar
- Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003;302(5650):1519–22.View ArticlePubMedGoogle Scholar
- WHO (2015) Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO, 2003–2015.Google Scholar
- Zhou NN, Senne DA, Landgraf JS, Swenson SL, Erickson G, Rossow K, Liu L, Yoon K, Krauss S, Webster RG. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol. 1999;73(10):8851–6.PubMed CentralPubMedGoogle Scholar